Sexual Dysfunction in Psychiatric Inpatients The Role of Antipsychotic Medication

Abstract

Introduction: Sexual dysfunction is a common side effect of antipsychotic medication. Although increased prolactin levels caused by antipsychotic agents are believed to play a major role with regard to sexual side effects, the underlying mechanism of antipsychotic agent-induced sexual dysfunction remains poorly understood.

Methods: In a multicentric study 587 psychiatric inpatients were assessed by means of a self-rating sexual questionnaire. Focussing on antipsychotic treatment three subgroups were drawn from the original sample. One group was treated with prolactin-increasing antipsychotics (n=119), the other with prolactin-neutral medication (n=109) and the third patient group was comprised of non-medicated clinical controls (n=105).

Results: The majority of all patients (50-75%) reported at least minor sexual dysfunction. On comparison of the subgroups, only female patients treated with prolactin-increasing medication reported more severe sexual dysfunction. However, multiple regression analysis did not confirm an association between the type of treatment and sexual impairment.

Discussion: Sexual dysfunction frequently occurs in psychiatric inpatients treated with antipsychotics. Our findings only partly support the assumptions concerning a major role of prolactin-increasing neuroleptics for medication-induced sexual impairment.

References

• 1 Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?.  Drug Saf. 2006;  29 587-598
• 2 Aizenberg D, Modai I, Landa A, Gil-Ad I, Weizman A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine.  J Clin Psychiatry. 2001;  62 541-544
• 3 Baldwin DS, Mayers A. Sexual side-effects of antidepressant and antipsychotic drugs.  Advances in Psychiatric Treatment. 2003;  9 202-210
• 4 Bender S, Grohmann R, Engel RR, Degner D, Dittmann-Balcar A, Ruther E. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics.  Pharmacopsychiatry. 2004;  37 ((Suppl 1)) S46-53
• 5 Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F, Porras A. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.  J Sex Marital Ther. 2003;  29 125-147
• 6 Byerly MJ, Nakonezny PA, Bettcher BM, Carmody T, Fisher R, Rush AJ. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.  Schizophr Res. 2006;  86 244-250
• 7 Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A. Prevalence of sexual dysfunction among newer antidepressants.  J Clin Psychiatry. 2002;  63 357-366
• 8 Cohen S, Huber TJ. Stichtagserhebung zu Störungen der Sexualität bei stationär behandelten, psychisch kranken Menschen.  Nervenarzt. 2006;  , in press
• 9 Cohen S, Kühn KU, Bender S, Erfurth A, Gastpar M, Murafi A, Rothermund M, Signerski J, Sträter B, Teusch L, Weig W, Welling A, Westheide J, Huber TJ. Sexual impairment in psychiatric inpatients: Focus on depression.  Pharmacopsychiatry. 2007;  , in press
• 10 Costa AM, de Lima MS, Faria M, Rodrigues Filho S, De Oliveira IR, Mari JD. A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia.  J Psychopharmacol. 2006;  , [epub ahead of print]
• 11 Cutler AJ. Sexual dysfunction and antipsychotic treatment.  Psychoneuroendocrinology. 2003;  28 ((Suppl 1)) 69-82
• 12 Dickson RA, Glazer WM. Hyperprolactinemia and male sexual dysfunction.  J Clin Psychiatry. 1999;  60 125
• 13 Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A, Shakhnovich T, Akram A, Pecenak J, McBride M, Treuer T. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.  Eur Psychiatry. 2006;  21 251-258
• 14 Fortier P, Mottard JP, Trudel G, Even S. Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults.  Schizophr Bull. 2003;  29 559-572
• 15 Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels.  Expert Opin Pharmacother. 2002;  3 1381-1391
• 16 Grohmann R, Engel RR, Ruther E, Hippius H. The AMSP drug safety program: methods and global results.  Pharmacopsychiatry. 2004;  37 (Suppl 1) S4-11
• 17 Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.  J Clin Psychiatry. 1999;  60 ((Suppl 23)) 14-19
• 18 Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.  Curr Med Res Opin. 2004;  20 189-197
• 19 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiatry. 2006;  39 47-51
• 20 Kühn KU, Westheide J. Pharmakoinduzierte Sexualstörungen. In: Linden M, Walter W, Rehabilitationspsychopharmakotherapie. Köln: Deutscher Ärzte Verlag 2005: 337-354
• 21 Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.  J Clin Psychiatry. 2002;  63 ((Suppl 4)) 56-62
• 22 MacGrath BM, Tempier RP. Patients’ opinions of olanzapine and risperidone following long-term treatment: Results from a cross-sectional survey.  Pharmacopsychiatry. 2005;  38 147-157
• 23 Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.  J Clin Psychiatry. 2001;  62 ((Suppl 3)) 10-21
• 24 Perkins DO. Predictors of noncompliance in patients with schizophrenia.  J Clin Psychiatry. 2002;  63 1121-1128
• 25 Smith S, O’Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication.  Br J Psychiatry. 2002;  181 49-55
• 26 Tenback DE, van Harten PN, Slooff CJ, van Os J. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances.  Neuropsychopharmacology. 2006;  31 1832-1837
• 27 Weig W. Sexuelle Dysfunktionen aus nervenärztlicher Perspektive.  Nervenarzt. 2006;  77 101-109
• 28 Wirshing DA, Pierre JM, Marder SR, Saunders CS, Wirshing WC. Sexual side effects of novel antipsychotic medications.  Schizophr Res. 2002;  56 25-30

Correspondence